Silence Therapeutics appoints James Ede-Golightly to its Board as Non-Executive Director alongside Iain Ross joining as Non-Executive Chairman

– UK, London –  Silence Therapeutics, PLC (LON:SLN), a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, today announced that Iain Ross has joined as a Non-Executive Director and Chairman of the Board of Directors with immediate effect.

Silence also announces that James Ede-Golightly has joined as a Non-Executive Director and that Stephen Parker is stepping down as a Non-Executive Director, both with immediate effect.

Dr. David Horn Solomon, Chief Executive Officer of Silence Therapeutics, commented: “I’m very pleased to welcome Iain Ross and James Ede-Golightly to the Board of Directors. Iain brings with him extensive healthcare and governance experience and I am looking forward to working with him to build significant value for shareholders, patients and their caregivers. I would also like to thank Stephen for his service as a valued Board member and advisor.”About Iain Ross

Iain Ross is a highly experienced board director with a career in the international life sciences and technology sectors that spans 40 years. He held senior commercial roles at Sandoz, Fisons and Hoffman La Roche before moving into the biotechnology sector where he was Chairman and CEO of several international biotechnology companies. Currently he is Non-executive Chairman at Kazia Therapeutics Limited, e-Therapeutics plc and Redx Pharma plc. Mr Ross is a qualified Chartered Director, Fellow of the Institute of Directors and Honorary Fellow of Royal Holloway, London University. He previously served as Chairman of the Board of Silence Therapeutics, from 2005 to 2010.

Iain Ross, Incoming Chairman of the Board of Directors at Silence Therapeutics, commented: “I am delighted to be returning to Silence Therapeutics and I look forward to working with David, the new management team and all stakeholders. With a renewed strategy in place and a return to the clinic imminent I believe Silence now represents a fundamentally transformed value proposition and I am excited to work with the team and to bring some stability to the Board to deliver on its potential.”

About James Ede-Golightly

James Ede-Golightly joins Silence with extensive experience in finance, technology and company direction. He is currently Chairman of DeepMatter Group Plc and Oxford Advanced Surfaces Ltd and Non-executive Director at Oxehealth Limited. Mr Ede-Golightly was a founder of ORA Capital Partners in 2006, prior to which he worked as an analyst at Merrill Lynch Investment Managers and Commerzbank. Mr Ede-Golightly is a Chartered Director, a Chartered Financial Analyst and holds an MA in Economics from the University of Cambridge. In 2012 Mr Ede-Golightly was awarded New Chartered Director of the Year by the Institute of Directors.

About Silence Therapeutics plc

Silence Therapeutics is developing a new generation of medicines by harnessing the body’s natural mechanism of RNA interference, or RNAi, within its cells. Its proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using its enabling delivery systems, it has achieved an additional level of specificity by delivering its therapeutic RNA molecules exclusively to target cells. Silence’s proprietary RNA chemistries and delivery systems are designed to improve the stability of our molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases.

For more information :

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Comments are closed.